The University of Southampton
University of Southampton Institutional Repository

Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain

Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain
Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain

Intravenous immunoglobulin (IVIg) therapy is used to treat a wide range of autoimmune conditions and consists of pooled immunoglobulin G (IgG) from healthy donors. The immunosuppressive effects of IVIg are, in part, attributed to terminal α2,6-linked sialic acid residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain. This α2,6-sialylated Fc (sFc) has been reported to bind to the carbohydrate recognition domain (CRD) of the cell-surface lectin DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and its murine orthologue SIGN-R1 (specific intracellular adhesion molecule-grabbing non-integrin R1) and, via this interaction, to signal the downstream expression of immunosuppressive cytokines and receptors. Consistent with this model, the antiinflammatory effect of IVIg treatment is abolished in a murine knock-out of SIGN-R1 and can be restored by a knock-in with human DC-SIGN. In contrast, however, existing glycan array and X-ray crystallographic studies indicate that the CRDs of both SIGN-R1 and DC-SIGN bind to a restricted set of primarily oligomannose-type glycans that does not include the glycans found on sFc. We attempted to reconcile these immunological and biophysical observations. We first generated hypersialylated, desialylated, deglycosylated and untreated serum IgG and found that the affinity for the complete extracellular region of the DC-SIGN tetramer was similar for all antibody glycoforms. Moreover, the binding could be attributed to cross-reactive, polyclonal Fab (fragment antigen-binding) specificities in serum as neither recombinant Fc nor sFc bound to DC-SIGN. In addition, serum IgG exhibited no competition against known ligands of the DC-SIGN CRD. These findings lead us to suggest that IVIg therapy does not involve binding of IgG Fc to DC-SIGN and that alternative cell-surface lectins are required for the antiinflammatory activity of sFc.

antibody, Fc, glycosylation, IVIg, sialic acid
0022-2836
1253-1258
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Vasiljevic, Snezana
17e075b4-520d-4b9b-a4a7-08ac394ae5e1
Mitchell, Daniel A.
d489622a-19e8-43a0-87cd-ba866f5212c2
Crispin, Matthew
cd980957-0943-4b89-b2b2-710f01f33bc9
Scanlan, Christopher N.
04dd1b57-b6fc-414c-8595-08310dbb3d32
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Vasiljevic, Snezana
17e075b4-520d-4b9b-a4a7-08ac394ae5e1
Mitchell, Daniel A.
d489622a-19e8-43a0-87cd-ba866f5212c2
Crispin, Matthew
cd980957-0943-4b89-b2b2-710f01f33bc9
Scanlan, Christopher N.
04dd1b57-b6fc-414c-8595-08310dbb3d32

Yu, Xiaojie, Vasiljevic, Snezana, Mitchell, Daniel A., Crispin, Matthew and Scanlan, Christopher N. (2013) Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. Journal of Molecular Biology, 425 (8), 1253-1258. (doi:10.1016/j.jmb.2013.02.006).

Record type: Article

Abstract

Intravenous immunoglobulin (IVIg) therapy is used to treat a wide range of autoimmune conditions and consists of pooled immunoglobulin G (IgG) from healthy donors. The immunosuppressive effects of IVIg are, in part, attributed to terminal α2,6-linked sialic acid residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain. This α2,6-sialylated Fc (sFc) has been reported to bind to the carbohydrate recognition domain (CRD) of the cell-surface lectin DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and its murine orthologue SIGN-R1 (specific intracellular adhesion molecule-grabbing non-integrin R1) and, via this interaction, to signal the downstream expression of immunosuppressive cytokines and receptors. Consistent with this model, the antiinflammatory effect of IVIg treatment is abolished in a murine knock-out of SIGN-R1 and can be restored by a knock-in with human DC-SIGN. In contrast, however, existing glycan array and X-ray crystallographic studies indicate that the CRDs of both SIGN-R1 and DC-SIGN bind to a restricted set of primarily oligomannose-type glycans that does not include the glycans found on sFc. We attempted to reconcile these immunological and biophysical observations. We first generated hypersialylated, desialylated, deglycosylated and untreated serum IgG and found that the affinity for the complete extracellular region of the DC-SIGN tetramer was similar for all antibody glycoforms. Moreover, the binding could be attributed to cross-reactive, polyclonal Fab (fragment antigen-binding) specificities in serum as neither recombinant Fc nor sFc bound to DC-SIGN. In addition, serum IgG exhibited no competition against known ligands of the DC-SIGN CRD. These findings lead us to suggest that IVIg therapy does not involve binding of IgG Fc to DC-SIGN and that alternative cell-surface lectins are required for the antiinflammatory activity of sFc.

Text
2013-Dissecting the molecular mechanism of IVIg therapy the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
Restricted to Repository staff only
Request a copy

More information

e-pub ahead of print date: 13 February 2013
Published date: 26 April 2013
Keywords: antibody, Fc, glycosylation, IVIg, sialic acid

Identifiers

Local EPrints ID: 414543
URI: http://eprints.soton.ac.uk/id/eprint/414543
ISSN: 0022-2836
PURE UUID: 239b8a2d-69ab-4c8d-976f-271218bddb30
ORCID for Matthew Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 03 Oct 2017 16:31
Last modified: 16 Mar 2024 04:30

Export record

Altmetrics

Contributors

Author: Xiaojie Yu
Author: Snezana Vasiljevic
Author: Daniel A. Mitchell
Author: Matthew Crispin ORCID iD
Author: Christopher N. Scanlan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×